CAR-T cells, from principle to clinical applications

Coley, 1893, The treatment of malignant tumors by repeated inoculation of erysipelas: with a report of ten original cases, Am J Med Sci, 10, 487, 10.1097/00000441-189305000-00001 Decker, 2017, Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models, Front Immunol, 8 Miller, 1961, Immunological function of the thymus, Lancet, 278, 748, 10.1016/S0140-6736(61)90693-6 Allison, 1982, Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody, J Immunol, 129, 2293, 10.4049/jimmunol.129.5.2293 Waldman, 2020, A guide to cancer immunotherapy: from T cell basic science to clinical practice, Nat Rev Immunol, 20, 651, 10.1038/s41577-020-0306-5 Juric, 2016, Milestones of hematopoietic stem cell transplantation - From first human studies to current developments, Front Immunol, 7, 470, 10.3389/fimmu.2016.00470 Southam, 1966, Effect of leukocytes on transplantability of human cancer, Cancer, 19, 1743, 10.1002/1097-0142(196611)19:11<1743::AID-CNCR2820191143>3.0.CO;2-U Rosenberg, 1988, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, N Engl J Med, 319, 1676, 10.1056/NEJM198812223192527 Rosenberg, 1994, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, J Nat Cancer Inst, 86, 1159, 10.1093/jnci/86.15.1159 Rosenberg, 2011, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, 17, 4550, 10.1158/1078-0432.CCR-11-0116 Jochems, 2011, Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity, Exp Biol Med, 236, 567, 10.1258/ebm.2011.011007 Zhang, 2020, T Cell dysfunction and exhaustion in cancer, Front Cell Dev Biol, 8, 17, 10.3389/fcell.2020.00017 Maus, 2014, Antibody-modified T cells: CARs take the front seat for hematologic malignancies, Blood, 123, 2625, 10.1182/blood-2013-11-492231 Gross, 1989, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc Natl Acad Sci USA, 86, 10024, 10.1073/pnas.86.24.10024 Eshhar, 1993, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci USA, 90, 720, 10.1073/pnas.90.2.720 Hwu, 1993, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain, J Exp Med, 178, 361, 10.1084/jem.178.1.361 Moritz, 1994, lymphocytes with a grafted recognition specificity for ERBB2- expressing tumor cells, Proc Natl Acad Sci USA, 91, 4318, 10.1073/pnas.91.10.4318 Brocker, 2000, Chimeric Fv-ζ or Fv-ɛ receptors are not sufficient to induce activation or cytokine production in peripheral T cells, Blood, 96, 1999, 10.1182/blood.V96.5.1999 Finney, 1998, Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product - PubMed, J Immunol, 161, 2791, 10.4049/jimmunol.161.6.2791 Imai, 2004, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, 18, 676, 10.1038/sj.leu.2403302 Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021 Tammana, 2010, 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood t cells against b-cell malignancies, Hum Gene Ther, 21, 75, 10.1089/hum.2009.122 Ramos, 2018, In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas, Mol Ther, 26, 2727, 10.1016/j.ymthe.2018.09.009 Chmielewski, 2020, TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation, Adv Cell Gene Ther, 3 Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat Med, 9, 279, 10.1038/nm827 Tai, 2015, Targeting B-cell maturation antigen in multiple myeloma, Immunotherapy, 7, 1187, 10.2217/imt.15.77 Friedman, 2018, Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells, Hum Gene Ther, 29, 585, 10.1089/hum.2018.001 Wagner, 2020, CAR T Cell therapy for solid tumors: bright future or dark reality?, Mol Ther, 28, 2320, 10.1016/j.ymthe.2020.09.015 Depil, 2020, “Off-the-shelf” allogeneic CAR T cells: development and challenges, Nat Rev Drug Discov, 19, 185, 10.1038/s41573-019-0051-2 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931 Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025 Kochenderfer, 2017, Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy, Mol Ther, 25, 2245, 10.1016/j.ymthe.2017.07.004 Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Sommermeyer, 2016, Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, 30, 492, 10.1038/leu.2015.247 Turtle, 2016, Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8 Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134 Maude, 2014, Chimeric antigen receptor t cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Lee, 2016, Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic Stem Cell transplantation, Blood, 128 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Ritchie, 2013, Persistence and efficacy of second generation CAR T Cell against the LeY Antigen in acute myeloid leukemia, Mol Ther, 21, 2122, 10.1038/mt.2013.154 Mardiana, 2020, CAR T cells for acute myeloid leukemia: state of the art and future directions, Front Oncol, 10 Wang, 2015, Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia, Mol Ther, 23, 184, 10.1038/mt.2014.164 Arcangeli, 2017, Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia, Mol Ther, 25, 1933, 10.1016/j.ymthe.2017.04.017 Cummins, 2017, Treating Relapsed/Refractory (RR) AML with Biodegradable Anti-CD123 CAR modified T Cells, Blood, 130 Budde, 2017, Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial, Am Soc Hematol, 7 Liu, 2018, First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial, Blood, 132, 10.1182/blood-2018-99-110579 Fajgenbaum, 2020, Cytokine storm, N Engl J Med, 383, 2255, 10.1056/NEJMra2026131 Gust, 2017, Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 7, 1404, 10.1158/2159-8290.CD-17-0698 Parker, 2020, Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies, Cell, 183, 10.1016/j.cell.2020.08.022 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Wang, 2020, KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma, N Engl J Med, 382, 1331, 10.1056/NEJMoa1914347 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Abramson, 2020, Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, Lancet, 396, 839, 10.1016/S0140-6736(20)31366-0 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Raje, 2019, Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226 Wei, 2020, Clinical development of CAR T cell therapy in China: 2020 update, Cell Mol Immunol, 1